IMMUWHY

A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care (IMMUWHY)

II

interventionell

National

Durvalumab, Tremelimumab

Status: In Rekrutierung

Zeitraum

2020

2025

Zentren

20

5

Zentren gesucht

Patienten

50

9

30.03.2022

Klinische Settings

1st line, 2nd line

palliativ

Beteiligte

AIO-Arbeitsgruppen

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Förderer

AstraZeneca

Identifier

AIO-HEP-0119/ass

AIO-HEP-0119/ass

2018-004778-81

Kontakt

Leitung

Prof. Dr. med. Arndt Vogel

Ansprechpartner*in

Dr. Dörthe Vortmeyer
Telefon +49 69 7601-4196
E-Mail vortmeyer.doerthe@ikf-khnw.de